Especially, the S524L substitution in CDH6 has been predicted to be a strong neo-antigen (Figure 8A), peptides with such substitution could be utilized as potent adjuvants to trigger stronger anti-melanoma immunity when co-treated with other immuno-therapeutics such as anti-PD-1/L1 or anti-CTLA4 Abs. Here, CTLA4 is linked to melanoma.